drugset / Trial / NCT04371939
Efficacy and Safety of Romiplostim Versus Eltrombopag in the Treatment of Thrombocytopenia in Patients With Wiskott-Aldrich Syndrome
Phase 2
Unknown
30 enrolled
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
RandomizedCrossoverOpen-labelTreatment
Summary
This is a prospective, open-label, randomized, two-arm clinical trial conducted to evaluate the safety and efficacy of romiplostim in comparison with eltrombopag in the treatment of thrombocytopenia in patients with Wiskott-Aldrich syndrome
Timeline
- Start
- 2019-11-05
- Primary completion
- 2022-12
- Completion
- 2023-07-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Eltrombopag | Small molecule | 2 mg/kg | Oral |
| Subject | Eltrombopag | Small molecule | 3 mg/kg | Oral |
| Subject | Eltrombopag | Small molecule | 75 mg | Oral |
| Subject | Romiplostim | Peptide | 9 ug/kg | Subcutaneous |